sr141716 has been researched along with Migraine Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ankarali, S; Dagistan, Y; Kilinc, E; Torun, IE | 1 |
| Markert, A; Nozaki, C; Zimmer, A | 1 |
2 other study(ies) available for sr141716 and Migraine Disorders
| Article | Year |
|---|---|
Receptor mechanisms mediating the anti-neuroinflammatory effects of endocannabinoid system modulation in a rat model of migraine.
Topics: Animals; Calcitonin Gene-Related Peptide; Endocannabinoids; Male; Migraine Disorders; Neurogenic Inflammation; Nitroglycerin; Rats; Rimonabant; Substance P | 2022 |
Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
Topics: Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Benzamides; Cannabinoid Receptor Antagonists; Carbamates; Disease Models, Animal; Dose-Response Relationship, Drug; Endocannabinoids; Enzyme Inhibitors; Hyperalgesia; Male; Mice, Inbred C57BL; Mice, Knockout; Migraine Disorders; Monoacylglycerol Lipases; Nitroglycerin; Pain Measurement; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Touch; Trigeminal Nuclei | 2015 |